Moreover, Kaplan–Meier analyses of the GPPH cohort suggested that patients with CCA exhibiting low SPRYD4 expression had poorer OS (P = 2.854e-05) and DFS (P = 1.48e-02) than those with high expression (Fig. 2B-C). This evidence concerns the gene SPRYD4 and cholangiocarcinoma.